Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1969 2
1970 2
1971 1
1973 1
1975 1
1977 1
1978 1
1981 1
1985 1
1986 1
1987 4
1988 2
1989 1
1993 1
1994 2
1995 3
1996 1
1997 2
1998 2
1999 3
2000 5
2001 1
2002 6
2003 5
2004 3
2005 3
2006 2
2007 1
2009 2
2010 5
2011 2
2012 1
2013 3
2014 4
2015 4
2016 5
2017 3
2019 1
2020 2
2021 5
2022 3
Text availability
Article attribute
Article type
Publication date

Search Results

94 results
Results by year
Filters applied: . Clear all
Page 1
Phase 3, randomized, open-label study of pembrolizumab plus lenvatinib versus chemotherapy for first-line treatment of advanced or recurrent endometrial cancer: ENGOT-en9/LEAP-001.
Marth C, Tarnawski R, Tyulyandina A, Pignata S, Gilbert L, Kaen D, Rubio MJ, Frentzas S, Beiner M, Magallanes-Maciel M, Farrelly L, Choi CH, Berger R, Lee C, Vulsteke C, Hasegawa K, Braicu EI, Wu X, McKenzie J, Lee JJ, Makker V. Marth C, et al. Among authors: tarnawski r. Int J Gynecol Cancer. 2022 Jan;32(1):93-100. doi: 10.1136/ijgc-2021-003017. Epub 2021 Nov 19. Int J Gynecol Cancer. 2022. PMID: 34799418 Free PMC article.
Cilengitide combined with standard treatment for patients with newly diagnosed glioblastoma with methylated MGMT promoter (CENTRIC EORTC 26071-22072 study): a multicentre, randomised, open-label, phase 3 trial.
Stupp R, Hegi ME, Gorlia T, Erridge SC, Perry J, Hong YK, Aldape KD, Lhermitte B, Pietsch T, Grujicic D, Steinbach JP, Wick W, Tarnawski R, Nam DH, Hau P, Weyerbrock A, Taphoorn MJ, Shen CC, Rao N, Thurzo L, Herrlinger U, Gupta T, Kortmann RD, Adamska K, McBain C, Brandes AA, Tonn JC, Schnell O, Wiegel T, Kim CY, Nabors LB, Reardon DA, van den Bent MJ, Hicking C, Markivskyy A, Picard M, Weller M; European Organisation for Research and Treatment of Cancer (EORTC); Canadian Brain Tumor Consortium; CENTRIC study team. Stupp R, et al. Among authors: tarnawski r. Lancet Oncol. 2014 Sep;15(10):1100-8. doi: 10.1016/S1470-2045(14)70379-1. Epub 2014 Aug 19. Lancet Oncol. 2014. PMID: 25163906 Free article. Clinical Trial.
Volumetric staging in radiotherapy for oropharyngeal cancers.
Miszczyk M, Staniewska E, Jabłońska I, Lipka-Rajwa A, Stawiski K, Tarnawski R. Miszczyk M, et al. Among authors: tarnawski r. Tumori. 2021 Oct 9:3008916211050959. doi: 10.1177/03008916211050959. Online ahead of print. Tumori. 2021. PMID: 34628998
[Hereditary orotic aciduria].
Gmiński J, Tarnawski R, Drózdz M, Miska E. Gmiński J, et al. Among authors: tarnawski r. Pol Tyg Lek. 1987 Nov 23;42(47):1493-5. Pol Tyg Lek. 1987. PMID: 3328183 Review. Polish. No abstract available.
[Reye's syndrome].
Kopieczna-Grzebieniak E, Tarnawski R, Sliwa F. Kopieczna-Grzebieniak E, et al. Among authors: tarnawski r. Pediatr Pol. 1981 Nov-Dec;56(11-12):1389-94. Pediatr Pol. 1981. PMID: 7041072 Review. Polish. No abstract available.
The prognostic value of red cell distribution width (RDW), neutrophil-to-lymphocyte ratio (NLR), and platelet-to-lymphocyte ratio (PLR) in radiotherapy for oropharyngeal cancer.
Staniewska E, Tomasik B, Tarnawski R, Łaszczych M, Miszczyk M. Staniewska E, et al. Among authors: tarnawski r. Rep Pract Oncol Radiother. 2021 Dec 30;26(6):1010-1018. doi: 10.5603/RPOR.a2021.0126. eCollection 2021. Rep Pract Oncol Radiother. 2021. PMID: 34992875 Free PMC article.
94 results